Medifast’s fourth-quarter revenue declined 36.9% year over year to $75.1 million as active earning coaches fell 40.6% to 16,100. Average revenue per coach rose 6.2% to $4,664, while the company posted a net loss of $18.1 million and ended 2025 with $167.3 million cash.

CEO Dan Chard will step down effective June 1, 2026, remaining as chairman, with President Nick Johnson set to assume the chief executive role. The board’s succession plan reflects a continuation of the Metabolic Synchronization strategy under new leadership.

Medifast executed a restructuring expected to yield over $30 million in savings and repositioned from weight loss to broader metabolic health. The company reinstated 2026 revenue guidance of $270–$300 million and expects profitability improvements beginning in Q4 2026 as coach productivity gains materialize.